UNSPSC 51401903: Divaplon

This classification denotes a benzodiazepine with the molecular formula C17H17N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AOV43246G, chemically known as 6-ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl phenyl ketone but generally known as divaplon, which bears US NIH Compound Identifier 65822. European Medicines Agency schedules Divaplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06338MIG.

UNSPSC 51401903 Divaplon, a Commodity code, covers pharmaceutical products and drug-related systems that state and local governments procure for public health, addiction response, and pharmacy benefit programs. Recent solicitations show purchasing of naloxone (opioid reversal medication), drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through government health agencies and cooperative purchasing networks. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work spans acquisition of finished pharmaceutical products for direct distribution to community health facilities, establishment of direct-to-manufacturer prescription programs to reduce intermediaries and costs, and cooperative contracting with authorized pharmaceutical wholesalers to supply state and local government health programs across multiple jurisdictions.

Procurement activity under this code centers on Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to its community health building and a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit managers and wholesalers. The Minnesota Department of Administration's Office of State Procurement, on behalf of the multistate MMCAP cooperative, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities, with a response deadline of March 26, 2026 and contract awards effective July 1, 2026. Vendors must comply with FDA requirements, Good Manufacturing Practices, Drug Supply Chain Security Act certifications, and maintain relationships with authorized wholesalers; insurance requirements typically include commercial general liability of $2,000,000 to $5,000,000 per occurrence and professional liability coverage.